Morgan Stanley Lowers Arrowhead Price Target to $78 from $81, Maintains Equal Weight Rating.

Morgan Stanley lowered its price target for Arrowhead Pharmaceuticals to $78 from $81 and maintained an Equal Weight rating. The analyst expects multiple readouts this year, including Phase 3 SHTG data in Q3, but notes that meaningful sales are not expected in 2026. The firm also mentioned promising early familial chylomicronemia syndrome launch trends.